Beset by challenges with its Alzheimer’s disease drug, Biogen pivots

The company plans to let go of its CEO and scrap commercial plans for its controversial Alzheimer’s disease drug.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.